Recorded $51.7 million in net product sales of YUTREPIA™ as launch momentum continuesAchieved profitability in the first full quarter of YUTREPIA ...

November is Pulmonary Hypertension Awareness Month, and the American Lung Association, with support from Merck, is raising ...

In patients with pulmonary arterial hypertension (PAH), the use of anticoagulants was not associated with improvement in overall survival, and these results were confirmed by an updated meta-analysis.

Sotatercept, an activin-signaling inhibitor, reduces morbidity and mortality among patients with long-standing pulmonary arterial hypertension. Its effects in patients with pulmonary arterial ...

The target of AllRock Bio’s research is already validated by FDA-approved medicines — for the eyes. The biotech startup is expanding that science to the lungs with a drug candidate licensed from ...

NATICK, Mass., Sept. 16, 2025 /PRNewswire/ -- AllRock Bio Inc., a clinical-stage biotechnology company focused on advancing therapies for cardiopulmonary and fibrotic diseases, today announced a $50 ...

Evaluation for pulmonary hypertension (PH) in patients with cancer must include either lung ventilation/perfusion scan or dual-energy computed tomography of the chest to evaluate for acute and/or ...

Pulmonary hypertension (PH) is a significant global health challenge that profoundly impacts exercise tolerance and quality of life for affected individuals. While advancements in pharmacological ...

BOSTON & OSAKA, Japan--(BUSINESS WIRE)--Pahr Therapeutics, Inc. announced today that it has raised a $14M seed financing, led by RA Capital Management, AN Venture Partners and University of Tokyo Edge ...

As coordinator of the REHAR registry, you’ve had a unique perspective on pulmonary hypertension (PH) associated with respiratory diseases in Spain. What have been the most revealing insights from this ...